-
Featured
Low-risk Incidental Prostate Cancer in Men with Bladder Cancer May Be Associated with Longer Survival
Men with bladder cancer who have low-risk prostate cancer detected incidentally by radical cystoprostatectomy may actually have a more favorable prognosis than those who do not.
-
Featured
Ultrasound Therapy Yields Promising Results for Localized Prostate Cancer
At the American Urological Association's 2019 Annual Meeting, researchers presented the findings of a study on the effects transurethral ultrasound ablation (TULSA), a novel minimally invasive procedure that can reduce prostate size and prostate-specific antigens in patients with localized prostate cancer.
-
Featured
New Target Discovered for Prostate Cancer Immunotherapy
Genitourinary pathologists at Massachusetts General Hospital are the first to demonstrate that PD-L1 expression is highly prevalent in prostate tumor-associated nerves. Such nerves may represent an important target for immunotherapy regimens.
-
Prostate Cancer Patients with Posterior Positive Surgical Margins Have Poorer Prognosis
Shulin Wu, MD, PhD, and Chin-Lee Wu, MD, PhD, of the Departments of Urology and Pathology, present evidence that prostate cancer patients who have posterior positive surgical margins (PSM) after radical prostatectomy have a more aggressive disease than those with anterior PSM.
-
Editorial: MRI Promising for Prostate Cancer Screening in the Asymptomatic General Population
Commenting on a multicenter, prospective U.K. study, Susanna I. Lee, MD, PhD, and Aileen O'Shea, MBBCh, BAO, of the Department of Radiology, say it's now apparent that biparametric MRI is a promising method of community-based prostate cancer screening.
-
Computational Fluid Dynamics to Assess Urine Flow After Surgery for Benign Prostatic Hyperplasia
Chin-Lee Wu, MD, PhD, and colleagues have developed an innovative computational fluid dynamics model that simulate urine flow behavior within the prostatic urethra after transurethral surgery for benign prostatic hyperplasia.
Mass General Cancer Center
-
Adam Scott Feldman, MD, MPH
Director, Combined Harvard Urologic Oncology Fellowship, Urologic Oncologist, Department of Urology, Faculty, The Carol and James Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital
Recent Article
Considerations in Selecting Patients for Trimodal Therapy for Muscle-invasive Bladder Cancer
-
Chin-Lee Wu, MD, PhD
Associate Pathologist, Massachusetts General Hospital and Mass General Cancer Center, Associate Professor of Pathology, Harvard Medical School, Director, Genitourinary Pathology Services
Recent Article
Prostate Cancer Patients with Posterior Positive Surgical Margins Have Poorer Prognosis
-
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Associate Professor, Harvard Medical School
Recent Article
Prostate Cancer and Translational Research
-
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
